Merck KGaA Stock
€127.35
Your prediction
Merck KGaA Stock
Pros and Cons of Merck KGaA in the next few years
Pros
Cons
Performance of Merck KGaA vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Merck KGaA | 0.670% | -0.079% | 5.198% | -15.610% | 3.434% | -33.509% | -9.384% |
| Bayer AG | -1.080% | 3.236% | 25.727% | 108.409% | 21.614% | -20.126% | -11.603% |
| Biogen Inc. | -1.370% | -0.914% | -1.315% | 4.948% | -2.336% | -45.218% | -33.793% |
| Johnson & Johnson | 0.380% | 2.176% | 9.237% | 32.242% | 7.865% | 23.168% | 36.758% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Merck (US Symbol: MKGAF) operates within the dynamic pharmaceutical industry, and its financial performance reflects a blend of growth potential and certain challenges. With a solid market capitalization of approximately €72.1 billion and a range of strategic investments, Merck exhibits an underlying strength capable of sustaining its operations and exploring future growth avenues. Analyzing the financials provides a deeper understanding of both the strengths and weaknesses that shape the company's market position.
Strong Revenue Generation
Merck's total revenue for the most recent year stands at approximately €20.82 billion. This solid revenue base underscores the company's ability to generate substantial cash flow, crucial for funding operational activities, research and development (R&D), and other strategic initiatives.
Solid Profit Margins
The profit margin is reported at 13.07%, indicating that Merck is successful in converting a significant portion of its sales into net income. This efficiency is essential in maintaining a competitive edge within an industry characterized by high research and development costs.
Comments
News
2 Pharmaceutical Stocks Set to Rebound in 2026
The healthcare sector lagged broader equities last year. Novo Nordisk (NYSE: NVO) and Merck (NYSE: MRK), two pharmaceutical leaders, were among the underperformers. But here's the good news: There
2 Dirt Cheap Stocks to Buy With $200 Right Now
Some investors believe the market is currently overvalued. Hype and optimistic expectations, especially for artificial intelligence (AI) stocks, are baked into equity prices, or so the argument
2 Soaring Stocks to Hold for the Next 20 Years
There are few better, simpler, and more accessible ways to accumulate wealth over the long term than buying and holding shares of outstanding companies. And although it can be challenging to find